Scott Rocklage
InvestorFounding Partner at 5AM Ventures · Board director at Expansion Therapeutics · Board director at Cidara Therapeutics · Board director at Kinestral Technologies
Waltham, MA
Writes $100K – $5M checks · typically $1.5M
Find your path to Scott
65 people in our graph share verified history with Scott — schools, employers, funds. One of them is your warm intro.
About
Scott M. Rocklage is a chemist-turned-healthcare investor who joined 5AM Ventures as a Venture Partner in 2003 and became a Managing Partner in 2004. Before venture capital, he spent over two decades in healthcare management, holding leadership roles including Chairman and CEO of Cubist Pharmaceuticals and President/CEO/Chairman roles at Nycomed Salutar and Nycomed Interventional. His operating work contributed to the FDA approval of three New Drug Applications (Omniscan, Teslascan and Cubicin) and advanced six drug candidates into clinical trials. He holds a B.S. in Chemistry from UC Berkeley and a Ph.D. in Chemistry from MIT, and serves on the boards of several biotech companies.
Contact· published on Scott's own website
Invests in
BiotechHealthtechMedical Devices
Beyond investing
- Education
- Earned a B.S. in Chemistry from the University of California, Berkeley. Earned a Ph.D. in Chemistry from the Massachusetts Institute of Technology.
- Boards
- Serves on the Board of Associates at the Whitehead Institute.
- Awards
- His work contributed to the FDA approval of three U.S. New Drug Applications: Omniscan, Teslascan and Cubicin.
From Scott's own website — common ground for a warm intro.
Board director at Expansion Therapeutics
Intro paths
In turn, Scott can intro founders to Expansion Therapeutics's investors below.
Expansion Therapeutics's investors · 6
Co-founders at Expansion Therapeutics
Board director at Cidara Therapeutics
Intro paths
In turn, Scott can intro founders to Cidara Therapeutics's investors below.
Cidara Therapeutics's investors · 8
Co-founders at Cidara Therapeutics
Board director at Kinestral Technologies
Intro paths
In turn, Scott can intro founders to Kinestral Technologies's investors below.
Kinestral Technologies's investors · 2
Experience
- 5AM VenturesFounding Partnercurrent2018 — present
Deals · 5
Kinestral TechnologiesBoard seat
via 5AM Ventures · filed Jun 2018 · $54.6M raise
Cidara TherapeuticsBoard seat
via 5AM Ventures · filed Oct 2017 · $20.2M raise
RennoviaBoard seat
via 5AM Ventures · filed Feb 2017 · $6M raise
PulmatrixBoard seat
via 5AM Ventures · filed Jun 2015 · $210K raise
Pulmatrix OperatingBoard seat
via 5AM Ventures · filed Jun 2015 · $34.1M raise
Attribution from SEC filings, press coverage, and firm rosters.
Other disclosed investments
Board seats
AchaogenRelypsaSemprusVariationWaveRx
Investor
AchaogenApreaExpansion TherapeuticsNodtheraNouscomNovira TherapeuticsRelypsaSemprus BioSciencesVBI Vaccines
Sources: the investor's own website · SEC Form D filings · curated public sources.
Colleagues at 5AM Ventures
Network2
Investors connected to Scott in public investor directories — a warm-intro map.
Frequently asked questions
- Who is Scott Rocklage?
- Scott M. Rocklage is a chemist-turned-healthcare investor who joined 5AM Ventures as a Venture Partner in 2003 and became a Managing Partner in 2004. Before venture capital, he spent over two decades in healthcare management, holding leadership roles including Chairman and CEO of Cubist Pharmaceuticals and President/CEO/Chairman roles at Nycomed Salutar and Nycomed Interventional. His operating work contributed to the FDA approval of three New Drug Applications (Omniscan, Teslascan and Cubicin) and advanced six drug candidates into clinical trials. He holds a B.S. in Chemistry from UC Berkeley and a Ph.D. in Chemistry from MIT, and serves on the boards of several biotech companies.
- Where does Scott Rocklage work?
- Scott Rocklage is Founding Partner at 5AM Ventures and Board director at Expansion Therapeutics and Board director at Cidara Therapeutics and Board director at Kinestral Technologies.
- What does Scott Rocklage invest in?
- Scott Rocklage invests in Biotech, Healthtech, Medical Devices.
- What check size does Scott Rocklage write?
- Scott Rocklage typically writes checks of $100K – $5M.
- What boards does Scott Rocklage sit on?
- Scott Rocklage holds tracked board seats at Achaogen, Cidara Therapeutics, Kinestral Technologies, Pulmatrix, Pulmatrix, Pulmatrix Operating, Relypsa, Rennovia, Semprus, Variation.
- What companies has Scott Rocklage invested in?
- Investments tracked here include Achaogen, Aprea, Expansion Therapeutics, Nodthera, Nouscom, Novira Therapeutics, Pulmatrix, Relypsa, Rennovia, Semprus BioSciences, VBI Vaccines.
- Where did Scott Rocklage go to school?
- Scott Rocklage studied at Massachusetts Institute of Technology (Doctor of Philosophy - PhD, Chemistry); U.C. Berkeley.
- What awards has Scott Rocklage received?
- His work contributed to the FDA approval of three U.S. New Drug Applications: Omniscan, Teslascan and Cubicin.
Same school
Also attended Massachusetts Institute of Technology2,000
+ 1,994 more